Skip to main
INMD
INMD logo

Inmode Ltd (INMD) Stock Forecast & Price Target

Inmode Ltd (INMD) Analyst Ratings

Based on 5 analyst ratings
Buy
Strong Buy 20%
Buy 20%
Hold 60%
Sell 0%
Strong Sell 0%

Bulls say

InMode Ltd has demonstrated robust operational performance with the sale of 971 systems in Q2 2025, contributing to a global installed base growth to approximately 28,855 units, showcasing a 3.4% increase from the previous quarter. The company reported an operating margin of 27.5%, which surpassed expectations and reflected a year-over-year improvement of 40 basis points. Additionally, InMode's domestic sales reached $49.7 million in Q2 2025, indicating a positive reversal with a 9% growth from a decline of 7% in Q1 2025, driven by increasing consumer and physician engagement in the aesthetics market.

Bears say

InMode Ltd is facing a negative outlook primarily due to expected contraction in its profit margins, which, despite being among the highest in the med tech sector, are anticipated to decline. Additionally, the company's earnings per share (EPS) growth is projected to lag behind its revenue growth, indicating a potential inefficiency in translating revenue gains into profitability. Furthermore, a bear case scenario suggests a revenue compound annual growth rate (CAGR) of less than 5% over the next few years, driven by both weaker growth from existing products and slow adoption of new offerings.

Inmode Ltd (INMD) has been analyzed by 5 analysts, with a consensus rating of Buy. 20% of analysts recommend a Strong Buy, 20% recommend Buy, 60% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Inmode Ltd and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Inmode Ltd (INMD) Forecast

Analysts have given Inmode Ltd (INMD) a Buy based on their latest research and market trends.

According to 5 analysts, Inmode Ltd (INMD) has a Buy consensus rating as of Oct 14, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $18.65, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $18.65, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Inmode Ltd (INMD)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.